Home / English / Menopausal depression and bereavement
Category: Women’s Health · Menopause · Mental Health
Age ~52, Low Mood, Tears, and Grief Memories: Menopausal Depression and Care Options
Low mood, tearfulness, and resurfacing grief around age 50-plus can overlap menopause-transition depression, bereavement, and vasomotor/sleep disruption. Care often starts with PHQ-9 screening, MHT review by risk, and psychiatry for SSRI/SNRI or therapy when needed—not a promise for every person.
Critical red-flag symptoms
Seek emergency care or a crisis line now if any apply:
- Thoughts of self-harm or not wanting to live — in Thailand call 1323 (mental-health hotline) or go to emergency care
- Hopelessness so deep that basic daily tasks stop for days
- Severe sleeplessness for several nights with marked exhaustion
- Hearing or seeing things others do not, or unfounded beliefs of being harmed
- Severe flashes with palpitations, fainting, or unusual chest pressure
- Stopping work and all social contact from low mood without a care plan
These signs need urgent evaluation — do not wait for them to pass alone.
A common question in this life stage
Many people ask whether tearfulness when seeing old photos, body aches, insomnia, and hot–cold flashes mean menopause or depression. Clinically both can overlap. Self-care still matters, yet it does not rule out needing a medical assessment.
1. Estrogen, mood, and sad memories
During the menopause transition, ovarian hormone fluctuation is linked with major-depression risk in long-term cohorts, and dedicated guidance exists for assessing perimenopausal depression.
Check menopause symptom urgency
Review severity banding and get personalized guidance from our Advisory team
2. Vasomotor symptoms and insomnia that worsen mood
Vasomotor symptoms (hot–cold flashes) disrupt sleep. With chronic sleep loss, emotion regulation often falters, so aches and fatigue stack onto sadness.
Comparison: menopause-transition depression vs MDD vs grief
Dimensions, pattern cues, and talk-with-team directions
| Dimension | Menopause-transition depression | MDD | Grief / bereavement |
|---|---|---|---|
| Core pattern | Often with VMS, sleep loss, hormone flux | Clinical criteria by duration and severity | Centered on longing for the deceased |
| Common trigger context | Menopause transition | Multiple factors, including prior history | A loss event |
| Helpful tools | Menopause history + PHQ-9 | PHQ-9 + psychiatric assessment | Loss history + prolonged-grief screen |
| Care direction | Consider MHT by risk + mood support | SSRI/SNRI / psychotherapy per plan | Grief-focused therapy when criteria met |
3. PHQ-9, MHT, and SSRI/SNRI
PHQ-9 screening
PHQ-9 is a brief primary-care severity screen that opens a clinician conversation. Suicide ideation still needs direct questions every time.
Menopausal hormone therapy (MHT)
NAMS guidance frames hormone use by age, years since menopause, and personal risk. In some evidence, estradiol may help mood in selected transition-window candidates—not a medicine equally suited to everyone.
SSRI / SNRI
Medicines such as escitalopram (SSRI) or duloxetine (SNRI) may help mood, and some agents reduce hot-flash frequency/severity in selected studies. Choice and dose belong with psychiatry or the treating clinician.
Integrated care roadmap
Domain, practice, possible effect, cautions
| Domain | Practice | Possible effect | Caution |
|---|---|---|---|
| Screening | PHQ-9 + ask about self-harm thoughts | Clearer urgency banding | Not a standalone diagnosis |
| Hormones | Discuss MHT with a gynecologist | May ease VMS/sleep in some | Clot, stroke, cancer history |
| Mood medicines | SSRI/SNRI per psychiatry | Mood ± flash relief | Side effects, drug cautions |
| Psychotherapy | CBT / grief therapy when indicated | Tools for thoughts and loss | Needs ongoing specialist work |
Helpful steps vs risky patterns when mood drops
Practices that support care versus patterns that can worsen risk
| Dimension | Prefer | Riskier | Why |
|---|---|---|---|
| Asking for help | Book gynecology + psychiatry when mood impairs life | Staying alone for fear of seeming weak | Symptoms may be hormonal and depressive |
| Medicines/hormones | Follow the plan and scheduled follow-up | Self-buying or abrupt stopping | Contraindications and withdrawal risk |
| Sleep | Log night flashes and sleep quality | Long hypnotic use without cause review | VMS/depression may be the driver |
| Crisis | Call 1323 / emergency care for self-harm thoughts | Waiting for it to pass alone | Safety comes first |
4. Ongoing care and outcome boundaries
Useful plans usually track mood, sleep, flashes, and safety. Allowing memories of those who died—while clinicians support—is part of treatment, not a demand to forget. Many people improve with matched care; that is not a promise of the same timeline for everyone.
Frequently asked questions (FAQ)
Why can mood drop and old grief resurface around menopause?
Estrogen decline during the menopause transition is linked with depression risk and mood lability in multiple studies. When emotion regulation is strained, prior loss memories or grief can feel sharper—especially with insomnia and vasomotor symptoms.
How does estrogen relate to serotonin and mood?
Clinical models connect ovarian hormone fluctuation with serotonin signaling, neurosteroids, and the stress (HPA) axis. Rapid estrogen withdrawal may reduce emotional processing capacity and raise sadness sensitivity—this is physiology, not personal weakness.
How do menopausal depression, MDD, and grief differ?
Menopause-transition depression often co-occurs with vasomotor symptoms and hormone change. MDD is a clinical depressive syndrome by duration and severity. Grief/bereavement centers on longing for the deceased. They can overlap and need history plus tools such as PHQ-9.
What is PHQ-9 for, and can it replace a clinician visit?
PHQ-9 screens depression symptom severity and helps structure a clinician conversation. It is not a standalone diagnosis and does not replace suicide-risk assessment or treatment.
How can MHT and SSRI/SNRI help when low mood meets hot flashes?
MHT may help vasomotor symptoms, sleep, and mood in selected people by indication and personal risk. SSRI/SNRI medicines such as escitalopram or duloxetine may help mood and, in some evidence, hot flashes. Choices belong with gynecology and/or psychiatry.
If meditation and exercise are not enough, what does that mean?
Mindfulness and movement help many people, but clinical depression or severe hormone/sleep disruption may still need medical evaluation. That is not a failure of effort.
When should someone seek emergency or crisis mental-health care?
Seek emergency care or a mental-health hotline immediately if there are thoughts of self-harm or not wanting to live, profound hopelessness that blocks daily function, or severe sleeplessness for several nights. In Thailand, call 1323.
Can an online symptom score replace a clinic visit?
No. A menopause symptom score helps organize signals before talking with clinicians. It does not diagnose depression or authorize hormone or antidepressant use.
Scientific mechanism (author summary)
By Asst. Prof. Dr. Norawit Raatpiboon: in the menopause transition, estradiol fluctuation links to serotonin systems, neurosteroids, and the HPA axis, so emotion regulation can weaken. VMS fragment sleep and add affective load. With a loss history, grief can intensify under that physiology. Care usually reviews depression criteria (e.g., PHQ-9), MHT indication, and SSRI/SNRI or grief therapy options—without promising the same outcome for every person.
E-E-A-T and academic citations
- Maki PM, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause 2018. PMID 30179986
- Gordon JL, et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression. Am J Psychiatry 2015. PMID 25585035
- Bromberger JT, et al. Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med 2011. PMID 21306662
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001. PMID 11556941
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022. PMID 35797481
- Stubbs C, et al. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. 2017. PMID 28649145
- Cohen LS, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003. PMID 12900318
- Soares CN, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women. Menopause 2006. PMID 16894334
- Soares CN. Menopause and Mood: The Role of Estrogen in Midlife Depression and Beyond. Psychiatr Clin North Am 2023. PMID 37500244
- Mauro C, et al. The efficacy of complicated grief therapy for DSM-5-TR prolonged grief disorder. World Psychiatry 2022. PMID 35524621
- Glynne S, et al. Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort. 2025. PMID 40519046
Medical disclaimer
This article is educational only. It is not a diagnosis of depression, a hormone prescription, or a medication order for any individual. Decisions about MHT, SSRI/SNRI, and psychotherapy belong with the treating clinician. If there are thoughts of self-harm, call 1323 in Thailand or go to a hospital immediately.